Pregnancy LossNCT03442335
Implantation Test for Endometrial Receptivity
An observational study of Pregnancy Loss and Miscarriage, run by University of Birmingham at 6 sites in United Kingdom.
Trial summary
Background Miscarriage is the most frequent complication of pregnancy and represents the spontaneous loss of the embryo or foetus before it is able to survive independently (24 weeks of gestation). Read more about this study
- Who is it for?
- Ages 18 to 35 years, women only
- Conditions the study is for
- Pregnancy Loss, Miscarriage
- What is being tested?
- Chromohysteroscopy and Endometrial biopsy (Pipelle)
- Type of treatment
- Injection or infusion
- How many people
- 30 participants
- Where
- 6 sitesUnited Kingdom
- Study dates
- 12 Dec 2017to 31 Oct 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- No healthy volunteers
- Adult
Study population: A cohort of women who suffered unexplained recurrent miscarriage will be sub grouped in two study populations: women who suffered two or more miscarriages and women who suffered five or more miscarriages (extreme recurrent miscarriage cohort). A total of 60 women will be recruited for the study investigations (30 for chromohysteroscopy and 30 for endometrial biopsy). We will select a very narrow phenotype in order to increase the study's sensitivity and power. Participants will be 18-35 years old, not pregnant and regularly menstruating in order to reduce the age effect on the pregnancy outcome. They will be diagnosed as having unexplained recurrent miscarriage by undertaking the standard miscarriage investigations.
Who may be able to join
- women diagnosed with unexplained recurrent miscarriage (2+ miscarriages with negative standard miscarriage investigations)
- regular menstrual cycles
Who cannot join
- women who have irregular menstrual cycles or those who require fertility treatments
- any positive finding or health issue that may explain the diagnosis of recurrent miscarriage
- women who are pregnant at the time of the study investigations
- women who are participants in other interventional studies or trials
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
United Kingdom6 sites
Tommy's National Centre for Miscarriage Research
Birmingham, B15 2TG
North Bristol NHS Trust
Bristol
Countess of Chester Hospital HNS Foundation Trust
Chester
Royal Devon and Exeter NHS Foundation Trust
Exeter
Saint Mary's Hospital
Manchester
Royal Victoria Infirmary
Newcastle upon Tyne
About this study
Background Miscarriage is the most frequent complication of pregnancy and represents the spontaneous loss of the embryo or foetus before it is able to survive independently (24 weeks of gestation). It affects up to 50% of pregnancies with the vast majority (80%) occurring at pre-clinical stage before the woman recognises the pregnancy. Up to 5% of couples suffer recurrent miscarriage defined as 2-3 or more miscarriages leading to physical, emotional and financial consequences for couples, doctors and medical systems.
Different maternal health problems (thyroid disease, sticky blood, autoimmune disease, anatomical anomalies of the womb) and embryo defects may be responsible for some of the miscarriages; however, more than 50% of the occurrences have no identifiable cause based on the current diagnostic tests.
Read more
Aim The aim of the present research proposal is to understand the role of the lining of the womb in miscarriage and to explore the development of a potential implantation test that is cost-effective and may be implemented in clinical practice.
Methods Over a period of two years, women who suffered recurrent miscarriage will be approached in the advanced miscarriage clinic at Birmingham Women's Hospital during their routine appointment. Participants will be invited to participate by undergoing chromohysteroscopy and/or a biopsy from the lining of the womb during an outpatient appointment.
Chromohysteroscopy is based on a routine hysteroscopy which involves visualising the inside of the womb using a narrow telescope passed through the neck of the womb (cervix). "Chromo" comes from the fact that an iodine based dye will be injected to increase the power of the test.
The biopsy will be taken using a narrow plastic tube passed through the cervix. It is a standard diagnostic test for women with abnormal bleeding. As part of the present research, different cells and molecules will be analysed from the biopsy sample.
Read the detailed description
The Tommy's National Centre for Miscarriage Research in Birmingham is a Research Centre which brings together an interdisciplinary translational medicine research grouping jointly at the Birmingham Women's and Children's NHS Foundation Trust (BWCNFT) and the University of Birmingham (UoB). The overarching Tommy's Centre funding includes sites at the University of Warwick and Imperial College London. The Centre is dedicated to research across all aspects of miscarriage and early pregnancy complications including basic scientific, medical, social and ethical issues.
This research project will occur alongside an advanced miscarriage clinic at Birmingham Women's Hospital. The Study Office belongs to the University of Birmingham and is located within the Birmingham Women's Hospital (Academic Department, 3rd floor). Computers are linked to the University's Network and all the electronic data will be held within this network.
The research project is divided into a number of three work packages and the findings from these will build on each other. Therefore, we have incorporated each of these distinct work packages within this research project protocol, with methodological details and objectives of each.
Work package 1: Target Product Profile (TPP) The TPP will convey information regarding the proposed use, context of use, patients' and clinicians' needs for an endometrial test in relation to endometrial receptivity, recurrent miscarriage and recurrent implantation failure.
Women who suffer recurrent miscarriage are referred for routine care to the Recurrent Miscarriage Clinic within Birmingham Women's Hospital by their GP or by other NHS Early Pregnancy Units. Women attending the Recurrent Miscarriage Clinic will be invited to fill in a questionnaire during their waiting time prior to the consultation by one of the research nurses who work within the Recurrent Miscarriage Clinic. The purpose of the questionnaire is to gain insight into women's view and expectations in relation to a new endometrial receptivity test.
Work package 2: Chromohysteroscopy Hysteroscopy is the procedure in which the uterine cavity is viewed using a hysteroscope (lighted scope) inserted through the cervix. It is used routinely in the NHS for women with varying indications (ie: polyps or fibroids suspected on ultrasound, thin endometrium, adhesions etc). In addition to morphologic abnormalities (ie: septum, polyps, adhesions), hysteroscopy may identify direct visual appearances relevant to endometrial receptivity.
Chromohysteroscopy involves flushing the endometrial surface with a dye (ie: methylene blue) in order to increase the sensitivity of hysteroscopy for the diagnosis of subtle endometrial pathologies which have not produced macroscopic changes.
All previous chromohysteroscopic studies used methylene blue as a dye to enhance the visibility of endometrial abnormalities based on the ability of necrotic endometrial cells to absorb/retain the dye. The investigators plan to further develop this approach by using iodine in relation to the known endometrial properties.
It is well known that iodine interacts with glycogen to generate a brown-blue colour. The glycogen-iodine reaction normally enables the identification of high vaginal and cervical lesions during colposcopic examinations that women undergo routinely in the NHS when there is a suspicion on their smear tests.
The investigators hypothesise that aberrations in the secretory phase of the endometrial development may be identified using iodine chromohysteroscopy based on the interaction between iodine and glycogen which generates a brown-blue colour.
Work package 3: OMICS studies on endometrial samples Omics- refer to the application of high-throughput techniques which simultaneously examine changes in different molecular compartments: genomics, transcriptomics, proteomics, metabolomics etc. The understanding of human endometrial physiology and pathophysiology is being revolutionised by the use of omics-; however, current understanding of different complex phenotypes related to fertility remains incomplete, inconsistent and without strong clinical application.
A Pipelle biopsy of the endometrium involves passing a narrow plastic tube through the cervix to obtain a sample by aspiration. It is routinely used in the NHS to rule out endometrial hyperplasia/carcinoma in women suffering from heavy menstrual bleeding or postmenopausal bleeding.
The investigators hypothesise that women who suffered recurrent reproductive failure may have altered transcriptomics, proteomics, and metabolomics profiles in their endometrium. Identifying these changes may provide diagnostic and prognostic markers for future pregnancies.
- Conditions
- Pregnancy Loss, Miscarriage
- Being tested
- Chromohysteroscopy, Endometrial biopsy (Pipelle)
- Keywords
- embryo implantation, endometrial receptivity, chromohysteroscopy, transcriptomics, proteomics, metabolomics, implantation window, luteal phase
- Medical subject headings
- Abortion, Spontaneous
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ChromohysteroscopyDiagnostic test
Standard hysteroscopy followed by injection of a dye, in this case iodine.
Endometrial biopsy (Pipelle)Diagnostic test
Also called Endometrial sampling
A narrow plastic tube (Pipelle) is passed through the cervix to aspirate a sample of endometrial tissue.
| Study group | Role | What they receive |
|---|---|---|
| Recurrent miscarriage: 2+ miscarriages | Women who suffered 2 or more unexplained recurrent miscarriages. Receives: Diagnostic Test: Chromohysteroscopy; Diagnostic Test: Endometrial biopsy (Pipelle) | |
| Extreme recurrent miscarriage: 5+ miscarriages | Women who suffered 5 or more unexplained recurrent miscarriages. Receives: Diagnostic Test: Chromohysteroscopy; Diagnostic Test: Endometrial biopsy (Pipelle) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Iodine absorption
Iodine interaction with the mid luteal phase endometrium.
Measured: 2 years
Transcriptome profile
Transcriptomics analysis of endometrial samples.
Measured: 2 years
Proteome profile
Proteomics analysis of endometrial samples.
Measured: 2 years
Metabolome profile
Metabolomics analysis of endometrial samples.
Measured: 2 years
Secondary outcomes (2)
Miscarriage rate
Miscarriage rates in future pregnancies.
Measured: 5 years
Live birth rate
Live birth rates in future pregnancies.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Feb 2018
- Study start12 Dec 2017
- Primary completion30 Apr 2019
- Study completion31 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Pregnancy LossStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Birmingham
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Laurentiu Craciunas, Study chair, Tommy's National Centre for Miscarriage Research
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03442335
- Sponsor's protocol ID
- RG_17-179
- Other IDs
- 233994
- Status last verified
- Nov 2020
- First submitted
- 30 Jan 2018
- Last updated
- 4 Nov 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Upon reasonable request by December 2027.
Publications
Craciunas L, Pickering O, Chu J, Zurauskiene J, Coomarasamy A. Target Product Profile for an endometrial receptivity test: women's perspective. Eur J Obstet Gynecol Reprod Biol. 2020 Oct;253:42-47. doi: 10.1016/j.ejogrb.2020.07.058. Epub 2020 Aug 1.
PubMed 32771887Craciunas L, Pickering O, Chu J, Choudhary M, Zurauskiene J, Coomarasamy A. The transcriptomic profile of endometrial receptivity in recurrent miscarriage. Eur J Obstet Gynecol Reprod Biol. 2021 Jun;261:211-216. doi: 10.1016/j.ejogrb.2021.04.041. Epub 2021 Apr 30.
PubMed 33971384Craciunas L, Chu J, Pickering O, Mohiyiddeen L, Coomarasamy A. The metabolomic profile of endometrial receptivity in recurrent miscarriage. Minerva Obstet Gynecol. 2023 Dec;75(6):526-534. doi: 10.23736/S2724-606X.22.05151-X. Epub 2022 Oct 4.
PubMed 36193833
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implantation Test for Endometrial Receptivity
- ClinicalTrials.gov ID
- NCT03442335
- Acronym / sponsor ID
- RG_17-179
- Conditions
- Pregnancy Loss, Miscarriage
- Keywords
- embryo implantation, endometrial receptivity, chromohysteroscopy, transcriptomics, proteomics, metabolomics, implantation window, luteal phase
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- University of BirminghamUniversity, hospital or other
- Study start
- 12 Dec 2017 (actual)
- Primary completion
- 30 Apr 2019 (actual)
- Study completion
- 31 Oct 2022 (actual)
- First posted
- 22 Feb 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background Miscarriage is the most frequent complication of pregnancy and represents the spontaneous loss of the embryo or foetus before it is able to survive independently (24 weeks of gestation). It affects up to 50% of pregnancies with the vast majority (80%) occurring at pre-clinical stage before the woman recognises the pregnancy. Up to 5% of couples suffer recurrent miscarriage defined as 2-3 or more miscarriages leading to physical, emotional and financial consequences for couples, doctors and medical systems.
Different maternal health problems (thyroid disease, sticky blood, autoimmune disease, anatomical anomalies of the womb) and embryo defects may be responsible for some of the miscarriages; however, more than 50% of the occurrences have no identifiable cause based on the current diagnostic tests.
Aim The aim of the present research proposal is to understand the role of the lining of the womb in miscarriage and to explore the development of a potential implantation test that is cost-effective and may be implemented in clinical practice.
Methods Over a period of two years, women who suffered recurrent miscarriage will be approached in the advanced miscarriage clinic at Birmingham Women's Hospital during their routine appointment. Participants will be invited to participate by undergoing chromohysteroscopy and/or a biopsy from the lining of the womb during an outpatient appointment.
Chromohysteroscopy is based on a routine hysteroscopy which involves visualising the inside of the womb using a narrow telescope passed through the neck of the womb (cervix). "Chromo" comes from the fact that an iodine based dye will be injected to increase the power of the test.
The biopsy will be taken using a narrow plastic tube passed through the cervix. It is a standard diagnostic test for women with abnormal bleeding. As part of the present research, different cells and molecules will be analysed from the biopsy sample.
Detailed description
The Tommy's National Centre for Miscarriage Research in Birmingham is a Research Centre which brings together an interdisciplinary translational medicine research grouping jointly at the Birmingham Women's and Children's NHS Foundation Trust (BWCNFT) and the University of Birmingham (UoB). The overarching Tommy's Centre funding includes sites at the University of Warwick and Imperial College London. The Centre is dedicated to research across all aspects of miscarriage and early pregnancy complications including basic scientific, medical, social and ethical issues.
This research project will occur alongside an advanced miscarriage clinic at Birmingham Women's Hospital. The Study Office belongs to the University of Birmingham and is located within the Birmingham Women's Hospital (Academic Department, 3rd floor). Computers are linked to the University's Network and all the electronic data will be held within this network.
The research project is divided into a number of three work packages and the findings from these will build on each other. Therefore, we have incorporated each of these distinct work packages within this research project protocol, with methodological details and objectives of each.
Work package 1: Target Product Profile (TPP) The TPP will convey information regarding the proposed use, context of use, patients' and clinicians' needs for an endometrial test in relation to endometrial receptivity, recurrent miscarriage and recurrent implantation failure.
Women who suffer recurrent miscarriage are referred for routine care to the Recurrent Miscarriage Clinic within Birmingham Women's Hospital by their GP or by other NHS Early Pregnancy Units. Women attending the Recurrent Miscarriage Clinic will be invited to fill in a questionnaire during their waiting time prior to the consultation by one of the research nurses who work within the Recurrent Miscarriage Clinic. The purpose of the questionnaire is to gain insight into women's view and expectations in relation to a new endometrial receptivity test.
Work package 2: Chromohysteroscopy Hysteroscopy is the procedure in which the uterine cavity is viewed using a hysteroscope (lighted scope) inserted through the cervix. It is used routinely in the NHS for women with varying indications (ie: polyps or fibroids suspected on ultrasound, thin endometrium, adhesions etc). In addition to morphologic abnormalities (ie: septum, polyps, adhesions), hysteroscopy may identify direct visual appearances relevant to endometrial receptivity.
Chromohysteroscopy involves flushing the endometrial surface with a dye (ie: methylene blue) in order to increase the sensitivity of hysteroscopy for the diagnosis of subtle endometrial pathologies which have not produced macroscopic changes.
All previous chromohysteroscopic studies used methylene blue as a dye to enhance the visibility of endometrial abnormalities based on the ability of necrotic endometrial cells to absorb/retain the dye. The investigators plan to further develop this approach by using iodine in relation to the known endometrial properties.
It is well known that iodine interacts with glycogen to generate a brown-blue colour. The glycogen-iodine reaction normally enables the identification of high vaginal and cervical lesions during colposcopic examinations that women undergo routinely in the NHS when there is a suspicion on their smear tests.
The investigators hypothesise that aberrations in the secretory phase of the endometrial development may be identified using iodine chromohysteroscopy based on the interaction between iodine and glycogen which generates a brown-blue colour.
Work package 3: OMICS studies on endometrial samples Omics- refer to the application of high-throughput techniques which simultaneously examine changes in different molecular compartments: genomics, transcriptomics, proteomics, metabolomics etc. The understanding of human endometrial physiology and pathophysiology is being revolutionised by the use of omics-; however, current understanding of different complex phenotypes related to fertility remains incomplete, inconsistent and without strong clinical application.
A Pipelle biopsy of the endometrium involves passing a narrow plastic tube through the cervix to obtain a sample by aspiration. It is routinely used in the NHS to rule out endometrial hyperplasia/carcinoma in women suffering from heavy menstrual bleeding or postmenopausal bleeding.
The investigators hypothesise that women who suffered recurrent reproductive failure may have altered transcriptomics, proteomics, and metabolomics profiles in their endometrium. Identifying these changes may provide diagnostic and prognostic markers for future pregnancies.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Recurrent miscarriage: 2+ miscarriages | – | Diagnostic Test: Chromohysteroscopy, Diagnostic Test: Endometrial biopsy (Pipelle)Women who suffered 2 or more unexplained recurrent miscarriages. |
| Extreme recurrent miscarriage: 5+ miscarriages | – | Diagnostic Test: Chromohysteroscopy, Diagnostic Test: Endometrial biopsy (Pipelle)Women who suffered 5 or more unexplained recurrent miscarriages. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- A cohort of women who suffered unexplained recurrent miscarriage will be sub grouped in two study populations: women who suffered two or more miscarriages and women who suffered five or more miscarriages (extreme recurrent miscarriage cohort). A total of 60 women will be recruited for the study investigations (30 for chromohysteroscopy and 30 for endometrial biopsy). We will select a very narrow phenotype in order to increase the study's sensitivity and power. Participants will be 18-35 years old, not pregnant and regularly menstruating in order to reduce the age effect on the pregnancy outcome. They will be diagnosed as having unexplained recurrent miscarriage by undertaking the standard miscarriage investigations.
Key inclusion criteria (2 listed)
- women diagnosed with unexplained recurrent miscarriage (2+ miscarriages with negative standard miscarriage investigations)
- regular menstrual cycles
Key exclusion criteria (4 listed)
- women who have irregular menstrual cycles or those who require fertility treatments
- any positive finding or health issue that may explain the diagnosis of recurrent miscarriage
- women who are pregnant at the time of the study investigations
- women who are participants in other interventional studies or trials
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ChromohysteroscopyStandard hysteroscopy followed by injection of a dye, in this case iodine. | Diagnostic test | Extreme recurrent miscarriage: 5+ miscarriages, Recurrent miscarriage: 2+ miscarriages |
| Endometrial biopsy (Pipelle)Also: Endometrial samplingA narrow plastic tube (Pipelle) is passed through the cervix to aspirate a sample of endometrial tissue. | Diagnostic test | Extreme recurrent miscarriage: 5+ miscarriages, Recurrent miscarriage: 2+ miscarriages |
Primary outcome
Iodine absorption
Time frame: 2 years
Iodine interaction with the mid luteal phase endometrium.
Transcriptome profile
Time frame: 2 years
Transcriptomics analysis of endometrial samples.
Proteome profile
Time frame: 2 years
Proteomics analysis of endometrial samples.
Metabolome profile
Time frame: 2 years
Metabolomics analysis of endometrial samples.
2 secondary outcomes
Miscarriage rate
Time frame: 5 years
Live birth rate
Time frame: 5 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2022.
- Results publication: PubMed 32771887Craciunas L, Pickering O, Chu J, Zurauskiene J, Coomarasamy A. Target Product Profile for an endometrial receptivity test: women's perspective. Eur J Obstet Gynecol Reprod Biol. 2020 Oct;253:42-47. doi: 10.1016/j.ejogrb.2020.07.058. Epub 2020 Aug 1.
- Results publication: PubMed 33971384Craciunas L, Pickering O, Chu J, Choudhary M, Zurauskiene J, Coomarasamy A. The transcriptomic profile of endometrial receptivity in recurrent miscarriage. Eur J Obstet Gynecol Reprod Biol. 2021 Jun;261:211-216. doi: 10.1016/j.ejogrb.2021.04.041. Epub 2021 Apr 30.
- Results publication: PubMed 36193833Craciunas L, Chu J, Pickering O, Mohiyiddeen L, Coomarasamy A. The metabolomic profile of endometrial receptivity in recurrent miscarriage. Minerva Obstet Gynecol. 2023 Dec;75(6):526-534. doi: 10.23736/S2724-606X.22.05151-X. Epub 2022 Oct 4.
- Individual participant dataSharing planned: Yes. Upon reasonable request by December 2027.
Related trials for Pregnancy Loss
Not yet recruiting
e-Perinatal Butterfly: An Embedded Study for Parents Experiencing Perinatal Loss
Depressive Symptoms, Perinatal Loss
Not yet recruitingPhase 4
Azithromycin for Cerclage Prophylaxis
Cervical Insufficiency
RecruitingPhase 1
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma
Active, not recruitingObservational study
Factors Influencing Fertility or Pregnancy Health
Menstrual Cycles, Conception
RecruitingObservational study
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Solid Tumor, Adult, Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Laurentiu Craciunas study chair
Tommy's National Centre for Miscarriage Research
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pregnancy Loss and Miscarriage, run by University of Birmingham at 6 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Iodine absorption (time frame: 2 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03442335, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2022.